Journal ArticleDOI
Cardiac Resynchronization in Chronic Heart Failure
William T. Abraham,Westby G. Fisher,Andrew L. Smith,David B. Delurgio,Angel R. Leon,Evan Loh,Dusan Z. Kocovic,Milton Packer,Alfredo L. Clavell,David L. Hayes,Myrvin H. Ellestad,Robin J. Trupp,Jackie Underwood,Faith Pickering,Cindy Truex,Peggy McAtee,John C. Messenger +16 more
Reads0
Chats0
TLDR
Cardiac resynchronization results in significant clinical improvement in patients who have moderate-to-severe heart failure and an intraventricular conduction delay.Abstract:
Background Previous studies have suggested that cardiac resynchronization achieved through atrial-synchronized biventricular pacing produces clinical benefits in patients with heart failure who have an intraventricular conduction delay. We conducted a double-blind trial to evaluate this therapeutic approach. Methods Four hundred fifty-three patients with moderate-to-severe symptoms of heart failure associated with an ejection fraction of 35 percent or less and a QRS interval of 130 msec or more were randomly assigned to a cardiac-resynchronization group (228 patients) or to a control group (225 patients) for six months, while conventional therapy for heart failure was maintained. The primary end points were the New York Heart Association functional class, quality of life, and the distance walked in six minutes. Results As compared with the control group, patients assigned to cardiac resynchronization experienced an improvement in the distance walked in six minutes (+39 vs. +10 m, P=0.005), functional clas...read more
Citations
More filters
Patent
System and method for neural stimulation
Imad Libbus,Andrew P. Kramer,Anthony V. Caparso,Kristofer J. James,Stephen Ruble,Weiying Zhao +5 more
TL;DR: In this article, the authors proposed an implantable device that comprises at least one port, where each port is adapted to connect a lead with an electrode to the device, and the device further includes a stimulation platform, including a sensing circuit connected to the sensing circuit to sense an intrinsic cardiac signal and a stimulation circuit connected via a stimulation channel to deliver a stimulation signal to the electrode.
Journal ArticleDOI
A Prospective Randomized Evaluation of VV Delay Optimization in CRT‐D Recipients: Echocardiographic Observations from the RHYTHM II ICD Study
Giuseppe Boriani,Mauro Biffi,Cord Paul Müller,Karl-Heinz Seidl,Rainer Grove,Jürgen Vogt,Wilfried Danschel,Andreas Schuchert,Jean-Claude Deharo,Thorsten Becker,Eric Boulogne,Hans Joachim Trappe +11 more
TL;DR: Cardiac resynchronization therapy devices allow the programming of the atrioventricular (AV/PV) delays and the sequential stimulation of the ventricles via the inter ventricular (VV) delay.
Journal ArticleDOI
Recovery of normal ventricular function in patients with dilated cardiomyopathy: predictors of an increasingly prevalent clinical event.
Philip F. Binkley,Amanda Lesinski,Jeanette Pohorence Ferguson,Patricia S. Hatton,Laura Yamokoski,Sheetal Hardikar,Glen E. Cooke,Carl V. Leier +7 more
TL;DR: Five clinical variables that are independently associated with improvement of left ventricular ejection fraction to normal or near-normal values with medical therapy alone were identified and may be used to discriminate between patients in whom ventricular function will normalize with medical Therapy alone and those who will require more aggressive pharmacologic or device therapy.
Journal ArticleDOI
Preserved left ventricular ejection fraction following atrioventricular junction ablation and pacing for atrial fibrillation.
Lin Chen,David Hodge,Arshad Jahangir,Cevher Ozcan,R N Jane Trusty,Paul Friedman,Robert Rea,David Bradley,Peter Brady,Stephen Hammill,David L Hayes,Win-Kuang Shen +11 more
TL;DR: This data indicates that right ventricular apical pacing creates ventricular dyssynchrony and may compromise left ventricular ejection fraction (LVEF) in patients who have undergone atrioventricular junction ablation for atrial fibrillation.
Journal ArticleDOI
Comparison of effectiveness of cardiac resynchronization therapy in patients <70 versus ≥70 years of age
Gabe B. Bleeker,Martin J. Schalij,Sander G. Molhoek,Eric Boersma,Paul Steendijk,Ernst E. van der Wall,Jeroen J. Bax +6 more
TL;DR: In the present study, the effects of cardiac resynchronization therapy (CRT) in elderly patients were evaluated and compared with those in younger patients (age <70 years).
References
More filters
Book ChapterDOI
Nonparametric Estimation from Incomplete Observations
Edward L. Kaplan,Paul Meier +1 more
TL;DR: In this article, the product-limit (PL) estimator was proposed to estimate the proportion of items in the population whose lifetimes would exceed t (in the absence of such losses), without making any assumption about the form of the function P(t).
Book ChapterDOI
Regression Models and Life-Tables
TL;DR: The analysis of censored failure times is considered in this paper, where the hazard function is taken to be a function of the explanatory variables and unknown regression coefficients multiplied by an arbitrary and unknown function of time.
Journal ArticleDOI
Effects of Multisite Biventricular Pacing in Patients with Heart Failure and Intraventricular Conduction Delay
Serge Cazeau,Christophe Leclercq,Thomas Lavergne,S Walker,Varma C,Cecilia Linde,Stéphane Garrigue,Lukas Kappenberger,G A Haywood,Massimo Santini,Bailleul C,Jean-Claude Daubert,Multisite Stimulation in Cardiomyopathies (Mustic) Study Investigators +12 more
TL;DR: In this article, transvenous atriobiventricular pacemakers (with leads in one atrium and each ventricle) were used to reduce ventricular asynchrony.
Journal Article
The 6-minute walk: a new measure of exercise capacity in patients with chronic heart failure
Gordon H. Guyatt,Michael J. Sullivan,Penelope J. Thompson,Ernest L. Fallen,S. O. Pugsley,D W Taylor,Leslie B. Berman +6 more
TL;DR: It is concluded that the 6-minute walk is a useful measure of functional exercise capacity and a suitable measure of outcome for clinical trials in patients with chronic heart failure.
Journal ArticleDOI
Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial—the Losartan Heart Failure Survival Study ELITE II
Bertram Pitt,Philip A. Poole-Wilson,Robert Segal,Felipe Martinez,Kenneth Dickstein,A. John Camm,Marvin A. Konstam,Günter A.J. Riegger,George Klinger,James D. Neaton,Divakar Sharma,Balasamy Thiyagarajan +11 more
TL;DR: The ELITE II Losartan Heart Failure Survival Study as discussed by the authors showed an association between the angiotensin II antagonist losartan and an unexpected survival benefit in elderly heart-failure patients, compared with captopril, an ACE inhibitor.